LONDON, March 21, 2012 /PRNewswire/ --
Director appointment part of company's international corporate expansion
Healthcare specialist Westhouse Medical Services Plc ("Ticker Symbol 5WM") today announces, with immediate effect, the appointment of Mr. Jonathan Rothman as a non-executive director.
Rothman has over thirty years experience in the financial sector, most recently as a partner within the 'Met Group' where he was responsible for creating and structuring new companies within the business' portfolio, in Switzerland and the UK.
Previously Rothman spent fourteen years working with investment and portfolio consultants, advising and managing a number of fixed income funds, following a period as head of Swiss Franc equity derivatives at Cantor Fitzgerald.
Rothman started his career as a trader on the floor of the London Stock Exchange before moving into Eurobond trading with Swiss Bank Corporation International and Nikko Securities.
Jack Kaye, founder and CEO of Westhouse Medical Services commented: "We are pleased to welcome Jonathan on to the Westhouse Medical Services Board. He brings a wealth of business and financial sector experience to the company, which will be invaluable to us as we continue our acquisitive growth internationally within the healthcare sector."
Westhouse is currently developing a number of medical devices, including BreastCheck - a new low-cost, non-invasive breast cancer screening product which can act as a precursor to mammogram scanning. BreastCheck is due for launch in summer 2012.
Westhouse recently entered into negotiations for the acquisition of a majority stake in US listed Sunridge International. Sunridge's subsidiary, Ophthalmic International Inc., has developed a glaucoma procedure called PNT, which could revolutionise the way glaucoma is treated globally.
WESTHOUSE MEDICAL SERVICES PLC
For press information, contact:
Jo Lee / Sian Edwards/ George Baggaley
SOURCE Westhouse Medical Services Plc